People with nonsevere hemophilia (PWNSH) are phenotypically more diverse than those with severe hemophilia. Perceptions relating to a "nonsevere" phenotype have contributed to fewer research initiatives, fewer guidelines on optimal management, and a lack of standards for surveillance and clinical assessment for affected individuals. In many cases, episodes of abnormal bleeding could, if investigated, have led to earlier diagnosis. Furthermore, the major recent developments in therapy for hemophilia have largely focused on severe disease and, as a group, PWNSH have not been included in many key clinical trials. Benefiting people with severe disease, innovative replacement therapies have generally targeted factor levels that are above those present in a large proportion of PWNSH. Therapeutic advances can lead to improvement in phenotype for people with severe hemophilia over that currently experienced by many PWNSH. As a result, we are approaching a point where PWNSH may, in many countries, have a higher risk of bleeding and restriction in lifestyle than those with severe disease but with more limited therapeutic options. Given the multiple major advances in treatment for people with hemophilia, it is timely to review the aspects of nonsevere disease, to ensure equity in care and management for all individuals with this condition., Competing Interests: G.D. has received medical writing support for this manuscript from Sobi, consulting fees from Pfizer, BioMarin, CSL, Roche, and Sobi, and payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing, or educational events from Pfizer, Spark Therapeutics, CSL, Bayer, Takeda, Roche, Chugai, and Sobi.K.F. has received medical writing support for this manuscript from Sobi, grants from Novo Nordisk, CSL Behring, and Sobi, consulting fees from Roche and Sanofi, support for meeting attendance from Sobi, and has participated in data safety monitoring boards/advisory boards for Sanofi and Roche.P.J.L. has received medical writing support for this manuscript from Sobi, research grants to his institution from Pfizer, Roche, Sanofi, and Sobi, and participated in advisory board meetings for BioMarin, Sanofi, and Takeda.C.C. has received medical writing support for this manuscript from Sobi, as well as payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing, or educational events, and support for attending meetings and/or travel, from Sobi, Bayer, Roche, and Novo Nordisk. C.C. has also participated in data safety monitoring boards or advisory boards for Sobi, Bayer, Roche, and Novo Nordisk.M.L. has received medical writing support for this manuscript from Sobi, research funding from Takeda, consulting fees from Sobi, CSL Behring, Band Therapeutics, and Takeda, payment/honoraria from Takeda, Sobi, and Pfizer, support for meeting attendance from Takeda, and has roles in the WFH, EAHAD, FIGO, and ISTH., (The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).)